Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 5/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.40 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073978 | 0.91 | KMT2A (0.54) | KMT2ATLR2SIRT2TPSAB1 | |
| SCHEMBL14073977 | 0.90 | KMT2A (0.55) | KMT2ATLR2SIRT2CAPN1CAPN2 | |
| SCHEMBL14086291 | 0.88 | KMT2A (0.56) | KMT2ATLR2SIRT2 | |
| SCHEMBL14073967 | 0.87 | KMT2A (0.55) | KMT2ATLR2SIRT2CAPN1CAPN2 | |
| SCHEMBL14073973 | 0.87 | KMT2A (0.55) | KMT2ATLR2SIRT2 | |
| SCHEMBL17746997 | 0.86 | KMT2A (0.58) | KMT2ATLR2TLR1SIRT2 | |
| SCHEMBL17746999 | 0.86 | KMT2A (0.58) | KMT2ATLR2TLR1SIRT2 | |
| SCHEMBL30020706 | 0.86 | TLR2 (0.50) | KMT2ATLR2TLR1SIRT2 | |
| SCHEMBL30019865 | 0.86 | TLR2 (0.50) | KMT2ATLR2TLR1SIRT2 | |
| SCHEMBL14073721 | 0.85 | KMT2A (0.54) | KMT2ATLR2TLR1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234464-A1 | Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same | NGLY1, ELOVL6, ELOVL1 | KMT2A 1414/4885TLR2 1099/4885TLR1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.